1. Archive ›
  2. 2016 , №2, Vol. 4
Bashlakova E.E., Davidovskaya M.V., Evdoshenko E.P., Polyakova K.I., Skoromets A.A., Solodun I.Y., Fisun A.G., Khachanova N.V., Holownia M.A. 4376

Budget impact analysis of teriflunomide (aubagio) proposed inclusion into the programme ‘7 high-cost nosologies’ on the budgets of RF federal and regional public authorities in the field of healthcare to ensure treatment of multiple sclerosis patients

Budget impact analysis of teriflunomide inclusion as first-line disease modifying drugs (DMD) therapy in the List to ensure patients with relapsing-remitting multiple sclerosis (RRMS) within the programme ‘7 high-cost nosologies’ on the budgets of Russian Federation (RF) federal and regional public authorities in the field of health care.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link: Evdoshenko Е.P., Solodun I.Y., Bashlakova Е.Е., Holownia М.А., Polyakova К.I., Pokatilo А.G., Khachanova N.V., Davidovskaya М.V., Skoromets А.А. Budget impact analysis of teriflunomide (aubagio) proposed inclusion into the programme ‘7 high-cost nosologies’ on the budgets of RF federal and regional public authorities in the field of healthcare to ensure treatment of multiple sclerosis patients // Pharmacoeconomics: theory and practice. - 2016. - Vol.4, №2. - P.48-55 DOI: https://doi.org/10.30809/phe.2.2016.5

Comments0